Univariate and multivariate analysis for predictors of mortality during the first 10 years of the study, excluding those who die after their 10 year visit or who were lost to follow up at 10 years. Bromocriptine >1 year indicates those patients who were randomized to bromocriptine monotherapy and were able to continue bromocriptine monotherapy for at least 1 year
| Baseline variable | p Value | Odds ratio (95% CI) |
|---|---|---|
| Univariate analysis | ||
| Age at onset/10 y | <0.0013-150 | 3.08 (1.87–5.09) |
| Tremor/bradykinesia/rigidity form | 0.32 | 1.45 (0.70–3.00) |
| Hoehn and Yahr=3 | 0.05 | 2.14 (0.99–4.66) |
| Prestudy duration/y | 0.97 | 1.00 (0.81–1.23) |
| Prestudy progression rate | 0.0033-150 | 3.02 (1.45–6.29) |
| Balance disorder | 0.043-150 | 2.98 (1.07–8.30) |
| Dementia | 0.0093-150 | 4.46 (1.44–>10) |
| Symmetric disease | 0.32 | 1.44 (0.71–2.94) |
| NWUDS/5 points | 0.13 | 1.67 (0.85–3.27) |
| Columbia score/5 points | 0.0053-150 | 1.44 (1.11–1.85) |
| Bradykinesia/5 points | 0.033-150 | 1.61 (1.05–2.49) |
| Tremor/5 points | 0.023-150 | 3.41 (1.22–9.55) |
| Rigidity/5 points | 0.12 | 1.51 (0.88–2.56) |
| Female sex | 0.08 | 0.53 (0.25–1.10) |
| Randomisation to bromocriptine | 0.0483-150 | 2.07 (1.01–4.25) |
| Bromocriptine >1 y use | 0.30 | 1.26 (0.54–2.94) |
| Tremor as initial symptom | 0.043-150 | 2.14 (1.04–4.41) |
| Variable noted within 10 y | ||
| Confusion | 0.16 | 1.81 (0.79–4.16) |
| Hallucinations | 0.90 | 1.06 (0.46–2.43) |
| Dementia | 0.0013-150 | 3.75 (1.70–8.26) |
| Imbalance | 0.013-150 | 2.59 (1.25–5.35) |
| Multivariate analysis | ||
| Randomisation to bromocriptine | 0.023-150 | 2.99 (1.21–7.36) |
| Prestudy progression rate | 0.023-150 | 2.80 (1.15–6.79) |
| Age at onset per 10 years | <0.0013-150 | 3.10 (1.78–5.42) |
↵3-150 p<0.05.